Merck, Teva End Cancidas Patent Fight
Merck & Co. Inc. on Wednesday resolved a suit in New Jersey seeking to prevent Teva Pharmaceuticals USA Inc. from marketing a generic version of anti-fungal drug Cancidas....To view the full article, register now.
Already a subscriber? Click here to view full article